Related Experiment Video

Updated: Jun 10, 2026

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy
07:40

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy

Published on: May 26, 2023

Treatment of Takotsubo cardiomyopathy

Tomas Palecek1, Petr Kuchynka, Ales Linhart

  • 1Charles University of Prague, 1st Medical Faculty, 2nd Medical Department - Department of Cardiovascular Medicine, Prague, Czech Republic. tpalec@lf1.cuni.cz

Current Pharmaceutical Design
|July 17, 2010
PubMed

Insights

Takotsubo cardiomyopathy (TC), affecting postmenopausal women, involves temporary heart muscle dysfunction after stress. Current TC treatments are empirical, highlighting the need for clinical trials on effective management strategies.

Area of Science:

  • Cardiology
  • Internal Medicine

Background:

  • Takotsubo cardiomyopathy (TC) predominantly affects postmenopausal women.
  • It is characterized by transient left ventricular dysfunction triggered by emotional or physical stress.
  • Pathogenesis is linked to catecholamine-mediated myocyte injury and microvascular dysfunction.

Purpose of the Study:

  • To review the current understanding of Takotsubo cardiomyopathy pathogenesis.
  • To discuss empirical treatment strategies for TC in acute and stable phases.
  • To emphasize the need for randomized clinical trials in TC management.

Main Methods:

  • Literature review of Takotsubo cardiomyopathy.
  • Analysis of current therapeutic approaches.
  • Identification of knowledge gaps in TC management.

Main Results:

  • TC treatment is currently empirical and requires individualized approaches.
  • Alpha and beta blockade may prevent sympathetic overactivation in stable TC.
  • Beta blockers address dynamic left ventricular obstruction; phenylephrine is an option for hypotension with outflow obstruction.
  • Intra-aortic balloon pump counterpulsation is considered for hemodynamically unstable patients.

Conclusions:

  • No consensus exists on the chronic management of Takotsubo cardiomyopathy.
  • Randomized clinical trials are urgently needed to establish evidence-based treatment strategies for TC.

More Related Videos

Operating Transverse Aortic Constriction with Absorbable Suture to Obtain Transient Myocardial Hypertrophy07:02

Operating Transverse Aortic Constriction with Absorbable Suture to Obtain Transient Myocardial Hypertrophy

Published on: September 9, 2020

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Cardiomyopathy VI: Nursing Management01:29

Cardiomyopathy VI: Nursing Management

Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...